You have read all your free articles, to continue reading subscribe to read the rest of this content.
The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform development program. Biovian’s second-generation AAV platform willAlready a subscriber Login You have read all your free articles, to continue reading…
AstraZeneca and MSD have announced that the European Commission (EC) and the Japanese Ministry of Health, Labour and Welfare have approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The licensed indication is as a maintenance trAlready a subscriber Login You have read all your…
Orion Corporation has entered into an agreement with Chinese Jemincare, through which Orion will receive exclusive global development and commercialization rights, excluding the Greater China area (mainland China, Hong Kong, Macau and Taiwan), for a potent and selective NaV 1.8 blocker for the treatAlready a subscriber Login You have read…
AstraZeneca and Daiichi Sankyo have been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens. The approval by the EuropAlready a subscriber Login You have read…
